Precipio Q3-2026 revenue $7.3M, up 8% YoY to a record; Adjusted EBITDA $0.4M, operating cash flow $0.6M

Precipio, Inc.

Revenue $7.3M, up 8% YoY from $6.8M in Q3-2025 and above $7.0M in Q2-2026; product revenue $1.0M (+40% YoY), pathology revenue $6.3M (+5% YoY).
Adjusted EBITDA $0.4M vs $0.5M in Q3-2025 and $0.4M in Q2-2026; GAAP net income was roughly $0.0M versus a $0.1M net loss a year earlier.
Cash flow from operations $0.6M; total cash rose $0.5M to over $3.5M at September 30, 2026, versus $2.3M in Q3-2025.
CEO Ilan Danieli said pathology provides the financial foundation for growth and serves as the clinical validation platform for proprietary diagnostic products.
Management hosted a shareholder call at 5 PM ET on November 10, 2026; full results are in the Form 10-Q filed the same day.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.